Burford Brothers Inc. Purchases 8,214 Shares of Johnson & Johnson (NYSE:JNJ)

Burford Brothers Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 91.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,162 shares of the company's stock after acquiring an additional 8,214 shares during the quarter. Johnson & Johnson accounts for about 1.4% of Burford Brothers Inc.'s portfolio, making the stock its 14th largest position. Burford Brothers Inc.'s holdings in Johnson & Johnson were worth $2,846,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $29,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the fourth quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in Johnson & Johnson during the fourth quarter worth $38,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $0.82 on Friday, reaching $156.87. 7,866,488 shares of the company's stock were exchanged, compared to its average volume of 8,077,942. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm has a market cap of $377.44 billion, a price-to-earnings ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a fifty day simple moving average of $153.75 and a 200-day simple moving average of $154.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on JNJ shares. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Bank of America cut their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.